Drug Trial Radar · NCT06614816
Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years
Last checked: Nov 20, 2026Latest source record: Sep 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,200
Actual
Start
Feb 10, 2019
Primary completion
Jul 15, 2021
Study completion Jun 20, 2022
Sponsor
- Lead sponsor
- Southeast University, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Jiangsu CDC
- First posted
- Sep 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years: A Phase III, Randomized, Double-Blind, Active-Controlled Study
Conditions
- Chickenpox Vaccines
Interventions
Oka strain varicella attenuated live vaccineBiological
lyophilized powder, subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- seroconversion rateTime frame: 42 days after completing the full course of vaccination.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huaiyin District Center for Disease Control and Prevention
Huaian, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.